Bivalirudin

比伐芦定

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBivalirudin
Drug Alias Name比伐芦丁bivalirudine比伐卢定bivalirudinabivalirudinum +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProthrombin inhibitors
TargetsProthrombin
Therapy Area/IndicationsHemorrhageAcute DiseaseThrombocytopenia +[14] 
Global Approved IndicationsThrombocytopeniaThromboembolismAngina, Unstable +[4] 
Approved Indications in ChinaThrombocytopeniaThromboembolism
Original Approved Country/TerritoryUnited States
Original Approved Date2000/12/15
Country/TerritoryUnited StatesNetherlandsItaly +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesThe Medicines Company
China Registration ClassN/A

Develop Information

Active CompaniesMaia Pharms IncSandoz IncShenzhen Salubris Pharmaceuticals Co Ltd
Inactive CompaniesUniversity of Texas Southwestern Medical CenterThe Medicines Company Uk LtdClinica Mediterranea Spa +[8] 
Active IndicationsThrombocytopeniaThrombosisThromboembolism +[5] 
Inactive IndicationsHemorrhageAcute DiseaseVenous Thrombosis +[9] 

Other Information

ATC CodeB01AE06
Related LinksWikipediaDrugBankKEGG